Myomo Launches the MyoPro® 2x
April 30 2025 - 8:05AM
Business Wire
A Major Step Forward in Donning, Fit, and
Function - Enhancing User Independence
Myomo, Inc. (NYSE American: MYO), a wearable medical robotics
company that offers improved arm and hand function for individuals
with upper-limb paralysis and neuromuscular conditions, today
announced the launch of the MyoPro 2x, the latest evolution in its
flagship MyoPro product line.
Designed to enhance the user experience, the MyoPro 2x
introduces a reimagined approach to donning, empowering users with
a more intuitive, efficient, and consistent process to
independently put on their device, while improving fit and
function, which is expected to lead to enhanced clinical
outcomes.
“Our goals for these enhancements were primarily clinical. The
product development process was driven by inputs from users and
clinicians, along with Myomo’s own product performance data. This
patient and clinician focus was generated from the knowledge gained
from over 3000 patients who have received a MyoPro,” said Malcolm
Bock, Myomo’s V.P. Engineering and Product Strategy. “The MyoPro 2x
is our best product yet, and we are excited for the significant
patient impact of this launch.”
Highlights of the MyoPro 2x include streamlined and more
intuitive donning for a consistent fit for the patient, integrating
common customizations into the standard design in order to decrease
the time for clinicians to fit the MyoPro 2x to their individual
patients, and updated training documentation and instruction guides
for treating practitioners and users.
Supporting today’s launch, Myomo recently rolled out their full
certification process for Orthotic & Prosthetic providers to
become MyoPro Centers of Excellence to focus on the MyoPro 2x. This
process empowers practices to build their own patient pipelines
and, once fully certified, to treat patients with the technology
and dispense the MyoPro 2x independently.
“The MyoPro 2x is about more than innovation—it’s about putting
independence back into the hands of users,” said Paul R. Gudonis,
Chairman and CEO of Myomo. “This launch is the result of our
commitment to listen to clinicians and users alike and to deliver
meaningful improvements that make a real difference in daily life.
The MyoPro 2x furthers our leadership in this new and growing
space.”
About Myomo, Inc.
Myomo, Inc. is a medical robotics company that develops and
markets advanced myoelectric orthoses to restore function in
individuals with neuromuscular disorders and upper-limb paralysis.
Myomo's proprietary MyoPro® product line is the only commercial
device in the U.S. that, by sensing a patient’s EMG signals through
non-invasive sensors, can enable individuals to perform daily
activities such as eating, lifting objects, and more. Headquartered
in Burlington, Mass., Myomo is dedicated to transforming lives
through mobility.
Forward-looking Statements
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to
Myomo’s expectations concerning the MyoPro 2x, including
expectations for enhanced clinical outcomes and impact on patients.
These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond our control, which could cause actual results to differ
materially from those contemplated in these forward-looking
statements. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Except as required by law, Myomo
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by
Myomo, see the disclosure contained in our public filings with the
Securities and Exchange Commission including, without limitation,
our most recent Annual Report on Form 10-K.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250430226543/en/
Media Contact: Email: marketing@myomo.com Phone:
857-283-7543 Website: www.myomo.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Jun 2025 to Jul 2025
Myomo (AMEX:MYO)
Historical Stock Chart
From Jul 2024 to Jul 2025